单羧酸转运蛋白（MCT）的功能调控及生理特性研究

doi:10.14088/j.cnki.issn0439-8114.2022.13.031

摘要/Abstract

摘要： 单羧酸盐转运蛋白（MCT）属于溶质载体（SLC）转运蛋白家族,该家族由14个成员组成,依次命名为MCT1~14。MCT家族蛋白都由12个跨膜结构域组成,但各亚型间具有组织分布特异性和底物差异性,它们也参与多种生理和病理过程。MCT蛋白在恶性肿瘤与癌症细胞中高度表达,其转运活性需要其他辅助蛋白进行调控,如跨膜糖蛋白、碳酸酐酶、透明质酸受体、乳酸脱氢酶等,从而促进肿瘤细胞的侵袭和转移。MCT蛋白已被作为肿瘤治疗的潜在靶点,目前利用MCT的抑制剂进行肿瘤治疗方面已经取得了一些进展。主要对MCT的功能调控及其在肿瘤中的生理特性进行总结,为以MCT为靶点的抑制剂及药物的发现提供参考。

关键词: 单羧酸转运蛋白（MCT）, 活性调控, 肿瘤治疗, 靶向抑制剂

Abstract: Monocarboxylate transporters （MCTs） belong to the solute carrier （SLC） transporter family, which consists of 14 members, sequentially named MCT1~14. MCT family proteins are all composed of 12 transmembrane domains, but each subtype has tissue distribution specificity and substrate differences, and they are also involved in a variety of physiological and pathological processes. MCT protein is highly expressed in malignant tumors and cancer cells, and its transport activity needs to be regulated by other auxiliary proteins, such as transmembrane glycoprotein, carbonic anhydrase, hyaluronic acid receptor, lactate dehydrogenase, etc., thereby promoting tumor cell invasion and transfer. MCT proteins have been used as potential targets for tumor therapy and some progress has been made in tumor therapy using MCT inhibitors. This paper mainly summarizes the functional regulation of MCT and its physiological characteristics in tumors, and provides a reference for the discovery of MCT-targeted inhibitors and drugs.

Key words: monocarboxylate transporters（MCT）, activity regulation, tumor therapy, targeted inhibitors

中图分类号:

张维, 严汉池. 单羧酸转运蛋白（MCT）的功能调控及生理特性研究[J]. 湖北农业科学, 2022, 61(13): 165-172.

ZHANG Wei, YAN Han-chi. Functional regulation and physiological characteristics of monocarboxylic acid transporter （MCT）[J]. HUBEI AGRICULTURAL SCIENCES, 2022, 61(13): 165-172.

参考文献

[1] BELTON R J, CHEN L, MESQUITA F S, et al.Basigin-2 is a cell surface receptor for soluble basigin ligand[J]. Journal of biological chemistry, 2008, 283(26): 17805-17814.
[2] HADJIAGAPIOU C, BORTHAKUR A, DAHDAL R Y, et al.Role of USF1 and USF2 as potential repressor proteins for human intestinal monocarboxylate transporter 1 promoter[J]. American journal of physiology: Gastrointestinal and liver physiology, 2005, 288(6): 1118-1126.
[3] CUFF M A,SHIRAZI-BEECHEY S P. The human monocarboxylate transporter,MCT1:Genomic organization and promoter analysis[J]. Biochemical and biophysical research communications,2002, 292(4): 1048-1056.
[4] BORTHAKUR A, SAKSENA S, GILL R K, et al.Regulation of monocarboxylate transporter 1 (MCT1) promoter by butyrate in human intestinal epithelial cells: Involvement of NF‐κB pathway[J]. Journal of cellular biochemistry, 2008, 103(5): 1452-1463.
[5] DIEHL K, DINGES L A, HELM O, et al.Nuclear factor E2-related factor-2 has a differential impact on MCT1 and MCT4 lactate carrier expression in colonic epithelial cells: A condition favoring metabolic symbiosis between colorectal cancer and stromal cells[J]. Oncogene, 2018, 37(1):39-51.
[6] DOHERTH J R, YANG C, SCOTT K E, et al.Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis[J]. Cancer research, 2014, 74(3): 908-920.
[7] ULLAH M S, DAVIES A J, HALESTRAP A P.The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1α-dependent mechanism[J]. Journal of biological chemistry, 2006, 281(14): 9030-9037.
[8] NARUMI K, KOBAYASHI M, OTAKE S, et al.Regulation of human monocarboxylate transporter 4 in skeletal muscle cells: The role of protein kinase C (PKC)[J]. International journal of pharmaceutics, 2012, 428(1-2): 25-32.
[9] KNYAZEV E, MAL’TSEVA D, ZACHARYANTS A, et al. TNFα-induced expression of transport protein genes in HUVEC cells is associated with enhanced expression of transcription factor genes RELB and NFKB2 of the non-canonical NF-κB pathway[J]. Bulletin of experimental biology and medicine, 2018, 164(6): 757-761.
[10] HALESTRAP A P,PRICE N T.The proton-linked monocarboxylate transporter (MCT) family: Structure,function and regulation[J]. The biochemical journal,1999, 343(Pt 2):281-299.
[11] LEE W J, KIM M, PARK H-S, et al.AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARα and PGC-1[J]. Biochemical and biophysical research communications, 2006, 340(1): 291-295.
[12] BENTON C R, YOSHIDA Y, LALLY J, et al.PGC-1α increases skeletal muscle lactate uptake by increasing the expression of MCT1 but not MCT2 or MCT4[J]. Physiological genomics, 2008, 35(1): 45-54.
[13] ASADA K,MIYAMOTO K,FUKUTOMI T,et al.Reduced expression of GNA11 and silencing of MCT1 in human breast cancers[J]. Oncology, 2003, 64(4): 380-388.
[14] BOIDO R, VEGRAN F, MEULLE A, et al.Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors[J]. Cancer research, 2012, 72(4): 939-948.
[15] HALESTRAP A P.The monocarboxylate transporter family—structure and functional characterization[J]. IUBMB life, 2012, 64(1): 1-9.
[16] SASAKI S, KOBAYASHI M, FUTAGI Y, et al.Crucial residue involved in L-lactate recognition by human monocarboxylate transporter 4 (hMCT4)[J]. PloS One, 2013, 8(7): e67690.
[17] KINNE A, KLEINAU G, HOEFIG C S, et al.Essential molecular determinants for thyroid hormone transport and first structural implications for monocarboxylate transporter 8[J]. Journal of biological chemistry, 2010, 285(36): 28054-28063.
[18] HALESTRAP A P, MEREDITH D.The SLC16 gene family—from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond[J]. Pflügers archiv, 2004, 447(5): 619-628.
[19] BONEN A.The expression of lactate transporters (MCT1 and MCT4) in heart and muscle[J]. European journal of applied physiology, 2001, 86(1): 6-11.
[20] SONVEAUX P, VEGRAN F, SCHROEDER T, et al.Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice[J]. The journal of clinical investigation, 2008, 118(12):3930-3942.
[21] VAN HEE V F, PEREZ-ESCUREDO J, CACACE A, et al. Lactate does not activate NF-κB in oxidative tumor cells[J]. Frontiers in pharmacology, 2015, 6: 228.
[22] DHUP S, DADHICH RK, PORPORATO PE, et al.Multiple biological activities of lactic acid in cancer: Influences on tumor growth, angiogenesis and metastasis[J]. Current pharmaceutical design, 2012, 18(10): 1319-1330.
[23] GARCIA C K, BROWN M S, PATHAK R K, et al.cDNA cloning of MCT2, a second monocarboxylate transporter expressed in different cells than MCT1[J]. Journal of biological chemistry, 1995, 270(4): 1843-1849.
[24] PHILP N J,YOON H,LOMBARDI L.Mouse MCT3 gene is expressed preferentially in retinal pigment and choroid plexus epithelia[J]. American journal of physiology-cell physiology, 2001, 280(5): C1319-C1326.
[25] DE HEREDIA F P, WOOD I S, TRAYHURN P. Hypoxia stimulates lactate release and modulates monocarboxylate transporter (MCT1, MCT2, and MCT4) expression in human adipocytes[J]. Pflügers archiv-european journal of physiology, 2010, 459(3): 509-518.
[26] SETTLE P, MYNETT K, SPEAKE P, et al.Polarized lactate transporter activity and expression in the syncytiotrophoblast of the term human placenta[J]. Placenta, 2004, 25(6): 496-504.
[27] JONES R S, PARKER M D, MORRES M E.Quercetin, morin, luteolin, and phloretin are dietary flavonoid inhibitors of monocarboxylate transporter 6[J]. Molecular pharmaceutics,2017,14(9): 2930-2936.
[28] HUGO S E, CRUZ-GARCIA L, KARANTH S, et al.A monocarboxylate transporter required for hepatocyte secretion of ketone bodies during fasting[J]. Genes & development, 2012, 26(3): 282-293.
[29] FRIESEMA E C, GANGULY S, ABDALLA A, et al.Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter[J]. Journal of biological chemistry, 2003, 278(41): 40128-40135.
[30] MARIOTTA L, RAMADAN T, SINGER D, et al.T‐type amino acid transporter TAT1 (Slc16a10) is essential for extracellular aromatic amino acid homeostasis control[J]. The journal of physiology, 2012, 590(24): 6413-6424.
[31] FISEL P, SCHAEFFELER E, SCHWAB M.Clinical and functional relevance of the monocarboxylate transporter family in disease pathophysiology and drug therapy[J]. Clinical and translational science, 2018, 11(4): 352-364.
[32] CONSORTIUM S T D. Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico[J]. Nature, 2014, 506(7486): 97-101.
[33] ROSHANBIN S, LINDBERG F A, LEKHOLM E, et al.Histological characterization of orphan transporter MCT14 (SLC16A14) shows abundant expression in mouse CNS and kidney[J]. BMC neuroscience, 2016, 17(1): 1-14.
[34] MANOHARAN C, MANOHARAN C, WILSON M C, et al.The role of charged residues in the transmembrane helices of monocarboxylate transporter 1 and its ancillary protein basigin in determining plasma membrane expression and catalytic activity[J]. Molecular membrane biology, 2006, 23(6): 486-498.
[35] WILSON M C, MEREDITH D, FOX J E M, et al. Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: The ancillary protein for the insensitive MCT2 is EMBIGIN (gp70)[J]. Journal of biological chemistry, 2005, 280(29): 27213-27221.
[36] IACONO K T, BROWN A L, GREENE M I, et al.CD147 immunoglobulin superfamily receptor function and role in pathology[J]. Experimental and molecular pathology, 2007, 83(3): 283-295.
[37] OVENS M J, MANOHARAN C, WILSON M C, et al.The inhibition of monocarboxylate transporter 2 (MCT2) by AR-C155858 is modulated by the associated ancillary protein[J]. Biochemical journal, 2010, 431(2): 217-225.
[38] PHILP N J, OCHRIETOR J D, RUDOY C, et al.Loss of MCT1, MCT3, and MCT4 expression in the retinal pigment epithelium and neural retina of the 5A11/basigin-null mouse[J]. Investigative ophthalmology and visual science, 2003, 44(3): 1305-1311.
[39] KIRK Á, WILSON M, HEDDLE C, et al.CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression[J]. The EMBO journal, 2000, 19(15): 3896-3904.
[40] WILSON M C, MEREDITH D, HALESTRAP A P.Fluorescence resonance energy transfer studies on the interaction between the lactate transporter MCT1 and CD147 provide information on the topology and stoichiometry of the complex in situ[J]. Journal of biological chemistry, 2002, 277(5): 3666-3672.
[41] PHILP N J, WANG D, YOON H, et al.Polarized expression of monocarboxylate transporters in human retinal pigment epithelium and ARPE-19 cells[J]. Investigative ophthalmology and visual science, 2003, 44(4): 1716-1721.
[42] BELTON Jr R J, CHEN L, MESQUITA F S, et al. Basigin-2 is a cell surface receptor for soluble basigin ligand[J]. Journal of biological chemistry, 2008, 283(26): 17805-17814.
[43] HALESTRAP A P.The SLC16 gene family-structure, role and regulation in health and disease[J]. Molecular aspects of medicine, 2013, 34(2-3): 337-349.
[44] RUSU V, HOCH E, MERCADER J M, et al.Type 2 diabetes variants disrupt function of SLC16A11 through two distinct mechanisms[J]. Cell, 2017, 170(1): 199-212.
[45] CASTORINO J J, GALLAGHER-COLOMBO S M, LEVIN A V, et al. Juvenile cataract-associated mutation of solute carrier SLC16A12 impairs trafficking of the protein to the plasma membrane[J]. Investigative ophthalmology and visual science, 2011, 52(9): 6774-6784.
[46] VISSER W E, PHILP N J, van DIJK T B, et al. Evidence for a homodimeric structure of human monocarboxylate transporter 8[J]. Endocrinology, 2009, 150(11): 5163-5170.
[47] NOOR S I, DIETZ S, HEIDTMANN H, et al.Analysis of the binding moiety mediating the interaction between monocarboxylate transporters and carbonic anhydrase II[J]. Journal of biological chemistry, 2015, 290(7): 4476-4486.
[48] FORERO-QUINTERO L S, AMES S, SCHNEIDER H-P, et al. Membrane-anchored carbonic anhydrase IV interacts with monocarboxylate transporters via their chaperones CD147 and GP70[J]. Journal of biological chemistry, 2019, 294(2): 593-607.
[49] AMES S, ANDRING J T, MCKENNA R, et al.CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells[J]. Oncogene, 2020, 39(8): 1710-1723.
[50] FELMLEE M A,JONES R S,RODRIGUEZ-CRUZ V,et al.Monocarboxylate transporters (SLC16): Function, regulation, and role in health and disease[J]. Pharmacological reviews, 2020, 72(2): 466-485.
[51] PINHEIRO C, REIS R M, RICARDO S, et al.Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44[J]. Journal of biomedicine and biotechnology, 2010, 2010:427694.
[52] SLOMIANY M G, GRASS G D, ROBERTSON A D, et al.Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells[J]. Cancer research, 2009, 69(4): 1293-1301.
[53] HASHIMOTO T, HUSSIEN R, BROOKS G A.Colocalization of MCT1, CD147, and LDH in mitochondrial inner membrane of L6 muscle cells: Evidence of a mitochondrial lactate oxidation complex[J]. American Journal of physiology-endocrinology and metabolism, 2006, 290(6): e1237-e1244.
[54] PEREZ-ESCUREDO J, VAN HEE V F, SBOARINA M, et al. Monocarboxylate transporters in the brain and in cancer[J]. Biochimica et Biophysica Acta (BBA)-molecular cell research, 2016, 1863(10): 2481-2497.
[55] DE SAEDELEER C J, COPETTI T, PORPORATO P E, et al. Lactate activates HIF-1 in Oxidative but not in warburg-phenotype human tumor cells[J]. PloS One, 2012, 7(10): e46571.
[56] BALTAZAR F, PINHEIRO C, SANTOS F M, et al.Monocarboxylate transporters as targets and mediators in cancer therapy response[J]. Histolgy histopathology, 2014, 29(12):1511-1524.
[57] KENNEDY K M, DEWHIRST M W.Tumor metabolism of lactate: The influence and therapeutic potential for MCT and CD147 regulation[J]. Future oncology, 2010, 6(1): 127-148.
[58] PINHEIRO C,LONGATTO-FILHO A,AZEVEDO-SILVA J, et al.Role of monocarboxylate transporters in human cancers: State of the art[J]. Journal of bioenergetics and biomembranes, 2012, 44(1): 127-139.
[59] MIRANDA-GONCALVES V,HONAVAR M,PINHEIRO C, et al.Monocarboxylate transporters (MCTs) in gliomas: Expression and exploitation as therapeutic targets[J]. Neuro-Oncology, 2013, 15(2): 172-188.
[60] AFONSO J, SANTOS L L, MIRANDA‐GONCALVES V, et al. CD147 and MCT1‐potential partners in bladder cancer aggressiveness and cisplatin resistance[J]. Molecular carcinogenesis, 2015, 54(11): 1451-1466.
[61] EILERTSEN M, ANDERSEN S, AL-SAAD S, et al.Monocarboxylate transporters 1-4 in NSCLC: MCT1 is an independent prognostic marker for survival[J]. PloS One, 2014, 9(9): e105038.
[62] IZUMI H, TAKAHASHI M, URAMOTO H, et al.Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells[J]. Cancer science, 2011, 102(5): 1007-1013.
[63] PAYEN V L,HSU M Y,RADECKE K S,et al.Monocarboxylate transporter MCT1 promotes tumor metastasis independently of its activity as a lactate transporter[J]. Cancer research,2017,77(20):5591-5601.
[64] TASDOGAN A,FAUBERT B,RAMESH V,et al.Metabolic heterogeneity confers differences in melanoma metastatic potential[J]. Nature, 2020, 577(7788): 115-120.
[65] GRAY A L, COLEMAN D T, SHI R, et al.Monocarboxylate transporter 1 contributes to growth factor-induced tumor cell migration independent of transporter activity[J]. Oncotarget, 2016, 7(22): 32695.
[66] KONG S C, NOHR-NIELSEN A, ZEEBERG K, et al.Monocarboxylate transporters MCT1 and MCT4 regulate migration and invasion of pancreatic ductal adenocarcinoma cells[J]. Pancreas, 2016, 45(7): 1036-1047.
[67] HALESTRAP A P.Monocarboxylic acid transport[J]. Comprehensive physiology, 2011, 3(4): 1611-1643.
[68] OVENS M J, DAVIES A J, WILSON M C, et al.AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10[J]. Biochemical journal, 2010, 425(3): 523-530.
[69] BOLA B M, CHADWICK A L, MICHOPOULOS F, et al.Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport[J]. Molecular cancer therapeutics, 2014, 13(12): 2805-2816.
[70] NOBLE R A, BELL N, BLAIR H, et al.Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma[J]. Haematologica, 2017, 102(7): 1247.
[71] POLANSKI R, HODGKINSON C L, Fusi A, et al.Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer[J]. Clinical cancer research, 2014, 20(4): 926-937.
[72] GUAN X, RODRIGUEZ-CRUZ V, MORRIS M E.Cellular uptake of MCT1 inhibitors AR-C155858 and AZD3965 and their effects on MCT-mediated transport of L-lactate in murine 4T1 breast tumor cancer cells[J]. The AAPS journal, 2019, 21(2): 1-10.
[73] QUANZ M, BENDER E, KOPITZ C, et al.Preclinical efficacy of the novel monocarboxylate transporter 1 inhibitor BAY-8002 and associated markers of resistance[J]. Molecular cancer therapeutics, 2018, 17(11): 2285-2296.
[74] DRAOUI N, SCHICKE O, SERONT E, et al.Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux[J]. Molecular cancer therapeutics, 2014, 13(6): 1410-1418.
[75] WANG N, JIANG X, ZHANG S, et al.Structural basis of human monocarboxylate transporter 1 inhibition by anti-cancer drug candidates[J]. Cell, 2021, 184(2):370-383.